<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

ODAC Votes Against Safety Profile of Secura Bio’s P13K Inhibitor

Default sub title

minute read

Written by Biospace on September 26, 2022

In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra.

Topics: Press Coverage

Comments

Related Stories